|
Intergeneric
poliovirus recombinants for the treatment of malignant glioma
Gromeier
M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E
Department
of Molecular Genetics and Microbiology, State University of New York, Stony
Brook, NY 11794, USA
Poliovirus
neuropathogenicity depends on sequences within the 5' nontranslated region of
the virus.
Exchange of the poliovirus internal ribosomal entry site with its counterpart
from human rhinovirus type 2 resulted in attenuation of neurovirulence in
primates.
Despite deficient virus propagation in cells of neuronal origin, nonpathogenic
polio recombinants retain excellent growth characteristics in cell lines derived
from glial neoplasms.
Susceptibility of malignant glioma cells to poliovirus may be mediated by
expression of a poliovirus receptor, CD155, in glial neoplasms.
Intergeneric polio recombinants with heterologous internal ribosomal entry site
elements unfolded strong oncolytic potential against experimentally induced
gliomas in athymic mice.
Our observations suggest that highly attenuated poliovirus recombinants may have
applicability as biotherapeutic antineoplastic agents.
PMID:
10841575 [PubMed - indexed for MEDLINE]
|
